Pilot-Scale Study Of Human Plasma Proteomics Identifies ApoE And IL33 As Markers In Atopic Asthma

Overview

Journal J Asthma Allergy

Publisher Dove Medical Press

Date 2019 Oct 2

PMID 31571934

Citations 9

Authors

Moumita Bhowmik

Sreyashi Majumdar

Angira Dasgupta

Swati Gupta Bhattacharya

Sudipto Saha

Affiliations

Soon will be listed here.

Abstract

Background: The pathobiology of atopic asthma is complex and the symptoms similar to other respiratory diseases. As such, identification of biomarkers of atopic asthma is of prime importance for better diagnosis and control of the disease.

Objectives: We sought to study the changes in plasma proteome and cytokine-expression profile across healthy and atopic asthmatics for identifying biomarkers and exploring aberrant pathways for atopic asthma.

Methods: A pilot-scale study in humans was performed to identify differentially expressed proteins in blood plasma of healthy controls (n=5) and treatment-naïve atopic asthma patients (n=5) using quantitative label-free liquid chromatography-tandem mass spectrometry proteomics and ELISA.

Results: Mass spectrometry-based proteomic analysis revealed ApoE to be significantly downregulated in atopic asthmatics compared to healthy volunteers. Decreased expression of ApoE in atopic asthmatics was validated by immunoblotting (50.74% decrease). Comparison with atopic asthmatics and COPD patients showed that ApoE was decreased (36.33%) in atopic asthma compared to COPD. IL33 was significantly upregulated in atopic asthmatics compared to healthy subjects (3.84-fold).

Conclusion: ApoE was downregulated and IL33 upregulated in atopic asthma patients compared to healthy volunteers. These two proteins' profiles were distinct in atopic asthma from healthy and COPD plasma samples. Differential expression of these proteins could serve as a probable candidate for a two-protein classifier-based prognostic biomarker of atopic asthma.

Citing Articles

Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review.

Rezaeeyan H, Arabfard M, Rasouli H, Shahriary A, Gh B Immun Inflamm Dis. 2023; 11(11):e1090.

PMID: 38018577 PMC: 10659759. DOI: 10.1002/iid3.1090.

Elevated levels of interleukin-33 are associated with asthma: A meta-analysis.

Zhao R, Shi Y, Liu N, Li B Immun Inflamm Dis. 2023; 11(4):e842.

PMID: 37102668 PMC: 10116908. DOI: 10.1002/iid3.842.

Transcriptome analysis in patients with asthma after inhaled combination therapy with long-acting β2-agonists and corticosteroids.

Liang Y, Tzeng I, Hsieh P, Kuo C, Huang S, Yang M Int J Med Sci. 2022; 19(12):1770-1778.

PMID: 36313228 PMC: 9608042. DOI: 10.7150/ijms.76013.

Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.

Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando S Alzheimers Res Ther. 2022; 14(1):115.

PMID: 36002891 PMC: 9400269. DOI: 10.1186/s13195-022-01058-9.

Dynamic Urinary Proteome Changes in Ovalbumin-Induced Asthma Mouse Model Using Data-Independent Acquisition Proteomics.

Qin W, Wang T, Liu G, Sun L, Han W, Gao Y J Asthma Allergy. 2021; 14:1355-1366.

PMID: 34785909 PMC: 8590963. DOI: 10.2147/JAA.S330054.

References

Ray A, Raundhal M, Oriss T, Ray P, Wenzel S . Current concepts of severe asthma. J Clin Invest. 2016; 126(7):2394-403. PMC: 4922699. DOI: 10.1172/JCI84144. View

Sircar G, Saha B, Bhattacharya S, Saha S . Allergic asthma biomarkers using systems approaches. Front Genet. 2014; 4:308. PMC: 3884215. DOI: 10.3389/fgene.2013.00308. View

Griffiths C, Feder G, Wedzicha J, Foster G, Livingstone A, Marlowe G . Feasibility of spirometry and reversibility testing for the identification of patients with chronic obstructive pulmonary disease on asthma registers in general practice. Respir Med. 2000; 93(12):903-8. DOI: 10.1016/s0954-6111(99)90057-4. View

McLaren J, Michael D, Salter R, Ashlin T, Calder C, Miller A . IL-33 reduces macrophage foam cell formation. J Immunol. 2010; 185(2):1222-9. DOI: 10.4049/jimmunol.1000520. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Ray A, Oriss T, Wenzel S . Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2014; 308(2):L130-40. PMC: 4338947. DOI: 10.1152/ajplung.00070.2014. View

Murugan A, Prys-Picard C, Calhoun W . Biomarkers in asthma. Curr Opin Pulm Med. 2008; 15(1):12-8. DOI: 10.1097/MCP.0b013e32831de235. View

Saha S, Harrison S, Shen C, Tang H, Radivojac P, Arnold R . HIP2: an online database of human plasma proteins from healthy individuals. BMC Med Genomics. 2008; 1:12. PMC: 2396660. DOI: 10.1186/1755-8794-1-12. View

Fessler M . A New Frontier in Immunometabolism. Cholesterol in Lung Health and Disease. Ann Am Thorac Soc. 2017; 14(Supplement_5):S399-S405. PMC: 5711269. DOI: 10.1513/AnnalsATS.201702-136AW. View

10.

Yao X, Fredriksson K, Yu Z, Xu X, Raghavachari N, Keeran K . Apolipoprotein E negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway. Am J Respir Crit Care Med. 2010; 182(10):1228-38. PMC: 3001262. DOI: 10.1164/rccm.201002-0308OC. View

11.

Xia J, Zhao J, Shang J, Li M, Zeng Z, Zhao J . Increased IL-33 expression in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol. 2015; 308(7):L619-27. DOI: 10.1152/ajplung.00305.2014. View

12.

Kim S, Rhee C, Kim K, Lee S, Hwang H, Kim Y . Factors associated with plasma IL-33 levels in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017; 12:395-402. PMC: 5268328. DOI: 10.2147/COPD.S120445. View

13.

Antczak A, Domanska-Senderowska D, Gorski P, Pastuszak-Lewandoska D, Nielepkowicz-Gozdzinska A, Szewczyk K . Analysis of changes in expression of IL-4/IL-13/STAT6 pathway and correlation with the selected clinical parameters in patients with atopic asthma. Int J Immunopathol Pharmacol. 2016; 29(2):195-204. PMC: 5806727. DOI: 10.1177/0394632015623794. View

14.

Zybailov B, Florens L, Washburn M . Quantitative shotgun proteomics using a protease with broad specificity and normalized spectral abundance factors. Mol Biosyst. 2007; 3(5):354-60. DOI: 10.1039/b701483j. View

15.

Liew F, Pitman N, McInnes I . Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010; 10(2):103-10. DOI: 10.1038/nri2692. View

16.

Tsukamoto N, Takahashi N, Itoh H, Pouliquen I . Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin 5 monoclonal antibody, in healthy Japanese male subjects. Clin Pharmacol Drug Dev. 2016; 5(2):102-8. PMC: 5042051. DOI: 10.1002/cpdd.205. View

17.

Mayeux R . Biomarkers: potential uses and limitations. NeuroRx. 2005; 1(2):182-8. PMC: 534923. DOI: 10.1602/neurorx.1.2.182. View

18.

Perera F, Weinstein I . Molecular epidemiology: recent advances and future directions. Carcinogenesis. 2000; 21(3):517-24. DOI: 10.1093/carcin/21.3.517. View

19.

Gowdy K, Fessler M . Emerging roles for cholesterol and lipoproteins in lung disease. Pulm Pharmacol Ther. 2012; 26(4):430-7. PMC: 3466369. DOI: 10.1016/j.pupt.2012.06.002. View

20.

Backman H, Raisanen P, Hedman L, Stridsman C, Andersson M, Lindberg A . Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy. 2017; 47(11):1426-1435. DOI: 10.1111/cea.12963. View